Literature DB >> 3121226

Cellular and genetic analyses of IL-2 production and IL-2 receptor expression in a patient with familial T-cell-dominant immunodeficiency.

S Doi1, O Saiki, T Tanaka, K Ha-Kawa, T Igarashi, T Fujita, T Taniguchi, S Kishimoto.   

Abstract

Cellular and genetic analyses of interleukin-2 (IL-2) production and IL-2 receptor (IL-2R) expression were examined in a immunodeficient patient and his family members. Mononuclear cells (MNC) of the patient showed no proliferative response (stimulation index, less than 2) to T-cell mitogens (PHA and Con A) and were defective in IL-2 production and IL-2R expression (less than 1%), whereas productions of other lymphokines (B-cell differentiation factor and IFN-gamma) were not impaired significantly. His brother died of the same disease and his father also lacked in proliferative response and IL-2 production by PHA stimulation. In Southern blot analyses using DNA probes of IL-2 and IL-2R, patterns of the patient were the same as those of healthy volunteers, whereas the transcription of DNA coding for IL-2R to mRNA was lacking in the patient. These results suggest that inheritant defects of IL-2 production and IL-2R expression reside in this family and the defects are not linked to DNAs coding for IL-2 and IL-2R but to a transcriptional deficiency.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3121226     DOI: 10.1016/0090-1229(88)90003-7

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  3 in total

1.  Recombinant interleukin 2 therapy in severe combined immunodeficiency disease.

Authors:  R Pahwa; T Chatila; S Pahwa; C Paradise; N K Day; R Geha; S A Schwartz; H Slade; N Oyaizu; R A Good
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

2.  T cell immunodeficiency in dyskeratosis congenita.

Authors:  B W Lee; H K Yap; T C Quah; A Chong; C C Seah
Journal:  Arch Dis Child       Date:  1992-04       Impact factor: 3.791

3.  Primary T lymphocyte immunodeficiency associated with a selective impairment of CD2, CD3, CD43 (but not CD28)-mediated signal transduction.

Authors:  C Rodríguez-Gallego; A Arnaiz-Villena; A Corell; J Manzanares; M Timón; A Pacheco; J R Regueiro
Journal:  Clin Exp Immunol       Date:  1994-09       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.